Best of ASCO - 2014 Annual Meeting

 

Welcome

Other

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
Clinical activity, safety and tolerability of ASN002, a dual JAK/SYK inhibitor, in patients with non-Hodgkin lymphoma (NHL), myeolfibrosis (MF), chronic lymphocytic leukemia (CLL) and solid tumors.

Stefan K. Barta

TPS7084

Impact of rasburicase use in outpatient management of high uric acid.

Scott C. Howard

e19032